Skip to main content

 

Share Us: Email Icon Facebook icon Twitter Icon Facebook Like icon   Subscribe | Contact

Main menu

  • Home
  • About
    • About the Journal
    • Editorial Board
      • Role of Associate & Senior Editors
      • Board Disclosures
    • Supplemental Issues
    • Advertising
    • Subscribe
    • Recommend JAD
    • Related Links
      • Related IOS Press Journals
      • Upcoming Meetings
    • Contact
  • News
  • Submit
    • For Authors
    • Submission Guidelines
      • Submission Letter and Manuscript Transmission
      • Manuscript Preparation
      • Submission Checklist
      • Copyright
      • Permissions
    • Review Process
    • Publication Fee / Open Access Option
    • Proofs/Reprints
    • Policies
      • Financial Disclosure
      • Open Access Mandates
      • Preprints/Preprint Servers
      • Policy on Use of Human Subjects
      • Policy on Animal Use
      • Policy on Ethics
  • Contents
    • Current Issue
    • All Issues (including upcoming)
    • OnlineFirst Articles
    • Books
    • Letters to the Editor
  • Blog
  • Members
  • Rankings/Awards
  • Journal of Alzheimer's Disease Reports

Search JAD

User Top Menu

  • Welcome, Guest
  • Join
  • Log In

Main menu

  • Home
  • About
  • News
  • Submit
  • Contents
  • Blog
  • Members
  • Rankings/Awards
  • Journal of Alzheimer's Disease Reports
  • Home
  • About
    • About the Journal
    • Editorial Board
      • Role of Associate & Senior Editors
      • Board Disclosures
    • Supplemental Issues
    • Advertising
    • Subscribe
    • Recommend JAD
    • Related Links
      • Related IOS Press Journals
      • Upcoming Meetings
    • Contact
  • News
  • Submit
    • For Authors
    • Submission Guidelines
      • Submission Letter and Manuscript Transmission
      • Manuscript Preparation
      • Submission Checklist
      • Copyright
      • Permissions
    • Review Process
      • Information For Reviewers
      • Role of Associate & Senior Editors
    • Publication Fee / Open Access Option
    • Proofs/Reprints
      • Pre-Press/Proofs
      • Reprints
    • Policies
      • Financial Disclosure
      • Open Access Mandates
      • Preprints/Preprint Servers
      • Policy on Use of Human Subjects
      • Policy on Animal Use
      • Policy on Ethics
  • Contents
    • Current Issue
    • All Issues (including upcoming)
    • OnlineFirst Articles
    • Books
    • Letters to the Editor
  • Blog
    • Blog Guidelines
  • Members
  • Rankings/Awards
    • Alzheimer Award
    • Top 100
      • Top 100 Most Cited AD Investigators
      • Top 100 Most Prolific AD Investigators
      • The Article
    • Top 50 Results
  • Journal of Alzheimer's Disease Reports
    • Contents
    • Homepage

You are here

Home

Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.

Espay AJ, Herrup K, Imbimbo BP, Kepp KP, Daly T
J Alzheimers Dis. 2024; 99(3):877-881. PMID: 38701151. Abstract
  • Print
E-mail Icon
Comment Icon
  • Comment
Bookmark Icon Bookmark Recommend Icon Recommend Follow Icon Follow
  • Comment
| Bookmark | Recommend | Follow

CURRENT ISSUE

Volume 105, Issue 1
ISSN (p) 1387-2877
ISSN (e) 1875-8908

Sign up for JAD issue alerts!

BOOKS

Order AIAD Book Series

LATEST BOOKS:
Prevention and AD, AIAD Vol. 10
Intervention and AD, AIAD Vol. 11
Therapeutic Trials in AD, AIAD Vol. 12

 

JOURNAL INFO
  • About the Journal
  • Editorial Board
  • Supplemental Issues
  • Subscribe
SUBMIT
  • For Authors
  • ScholarOne
  • Review Process
  • Publication Fee
  • Submission Guidelines
CONTENT
  • Current Issue
  • All Issues
  • Articles OnlineFirst
RELATED LINKS
  • IOS Press Journals
  • Upcoming Meetings
SHARE

Facebook icon Twitter Icon Linkedin Icon GooglePlus Icon YouTube Icon

 

 

 

Disclaimer | Privacy Policy | Journal of Alzheimer’s Disease is published by IOS Press